Business Description
Cogent Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US19240Q2012
Total Employee Number:
258Description
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.63 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.39 | |||||
Debt-to-EBITDA | -0.69 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -1 | |||||
3-Year EPS without NRI Growth Rate | -6.7 | |||||
3-Year FCF Growth Rate | 1.2 | |||||
3-Year Book Growth Rate | 7.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.31 | |||||
9-Day RSI | 60.11 | |||||
14-Day RSI | 62.16 | |||||
3-1 Month Momentum % | -13.72 | |||||
6-1 Month Momentum % | -11.23 | |||||
12-1 Month Momentum % | 189.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 15.14 | |||||
Quick Ratio | 15.14 | |||||
Cash Ratio | 14.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -32.1 | |||||
Shareholder Yield % | -4.71 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -92.24 | |||||
ROA % | -62.7 | |||||
ROIC % | -880.25 | |||||
3-Year ROIIC % | -3171.35 | |||||
ROC (Joel Greenblatt) % | -1443.46 | |||||
ROCE % | -69.09 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 12.23 | |||||
Price-to-Tangible-Book | 12.22 | |||||
EV-to-EBIT | -17.37 | |||||
EV-to-Forward-EBIT | 4.72 | |||||
EV-to-EBITDA | -17.6 | |||||
EV-to-Forward-Revenue | 107.42 | |||||
EV-to-FCF | -21.23 | |||||
| Price-to-Net-Current-Asset-Value | 12.83 | |||||
| Price-to-Net-Cash | 11.64 | |||||
Earnings Yield (Greenblatt) % | -5.76 | |||||
FCF Yield % | -4.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:COGT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cogent Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.197 | ||
| Beta | 1.2222 | ||
| 3-Year Sharpe Ratio | 0.69 | ||
| 3-Year Sortino Ratio | 2.07 | ||
| Volatility % | 151.67 | ||
| 14-Day RSI | 62.16 | ||
| 14-Day ATR ($) | 1.603729 | ||
| 20-Day SMA ($) | 36.9685 | ||
| 12-1 Month Momentum % | 189.22 | ||
| 52-Week Range ($) | 10.38 - 43.73 | ||
| Shares Outstanding (Mil) | 170.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cogent Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cogent Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-03 | In 113 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 23 days | ||
| General meeting for 2026 | 2026-06-09 09:00 | 31.16 (-2.01%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 11:05 | 32.76 (-4.57%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 36.73 (+2.37%) | ||
| Leerink Healthcare Conference | 2026-03-11 10:40 | 36.68 (-0.57%) | ||
| Annual report for 2025 | 2026-02-17 | 36.53 (-0.84%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-17 | 36.53 (-0.84%) | ||
| 44(th) Annual J.P. Morgan Healthcare Conference | 2026-01-13 08:15 | 34.76 (+0.46%) | ||
| Guidance call for 2025 | 2025-12-08 08:00 | 38.77 (-1.75%) |
Show
Entries
Cogent Biosciences Inc Frequently Asked Questions
What is Cogent Biosciences Inc(COGT)'s stock price today?
The current price of COGT is $38.87. The 52 week high of COGT is $43.73 and 52 week low is $10.38.
When is next earnings date of Cogent Biosciences Inc(COGT)?
The next earnings date of Cogent Biosciences Inc(COGT) is 2026-08-05 Est..
Does Cogent Biosciences Inc(COGT) pay dividends? If so, how much?
Cogent Biosciences Inc(COGT) does not pay dividend.
Guru Commentaries on NAS:COGT
No articles.
Press Release
Articles on Cogent Biosciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers